Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
Research ArticleFocus: Anticoagulation

Oral Anticoagulants

David L McGlasson
American Society for Clinical Laboratory Science April 2004, 17 (2) 107-112; DOI: https://doi.org/10.29074/ascls.17.2.107
David L McGlasson
is a Research Clinical Laboratory Scientist at the 59th Clinical Research Suadron, Lockland AFB TX
MS CLS(NCA)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: david.mcglasson@lackland.af.mil
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. David L McGlasson, MS CLS(NCA)⇑
    1. is a Research Clinical Laboratory Scientist at the 59th Clinical Research Suadron, Lockland AFB TX
  1. Address for correspondence: David L McGlasson MS CLS(NCA), Department of the Air Force, 59 MDW/MSRL, 2200 Berquist Dr, Ste 1, Lackland AFB TX 78236-5300. (210) 292-6555, (210) 292-6053 (fax). david.mcglasson{at}lackland.af.mil

Extract

HISTORY OF ORAL ANTICOAGULATION The discovery of oral medications to control thrombotic disorders in humans probably started with a report in 1922 by U.S. veterinarian Frank W Schofield. Dr Schofield reported a bleeding diathesis in cattle that simulated hemorrhagic septicemia and “black leg syndrome”. He hypothesized that this disorder was due to feeding spoiled sweet clover to the cattle.1

In 1935, while studying the sterol metabolism of chicks in Copenhagen, 1943 Nobel Prize winner Henrik Dam discovered a bleeding tendency in the chicks fed a diet deficient in lipids. These results suggested the chicks lacked a substance necessary for normal coagulation; “Koagulations-Vitamin” or vitamin K. He studied this vitamin further with respect to its occurrence and biological function in animals and plants as well as its application in human medicine.2

In 1933 a Wisconsin farmer arrived at Karl Paul Link's laboratory at the University of Wisconsin-Madison with a pail of blood that would not coagulate. He also brought a small heap of spoiled sweet clover and a dead heifer in the back of his truck. Isolation and purification of the hemorrhagic compound led to the discovery of dicumarol (3,3-methylene-bis- {4-hyroxycoumarin}).3 Clinical studies were immediately started on this compound, establishing the basis for rodenticides and the first oral anticoagulant. The compound greatly diminished prothrombin activity and delayed the clotting mechanism in blood. The first prophylactic and therapeutic effects and the drug's mechanism in influencing deep vein thrombosis were described in 1942.4-6 Link, in 1948, went to the director of the Wisconsin…

ABBREVIATIONS: AMS = anticoagulation management service; DVT = deep vein thrombosis; GLA = gamma-carboxyl glutamic acid; GLU = glutamic acid; INR = international normalized ratio; IRP = international reference plasma; ISI = international sensitivity index; OAT = oral anticoagulant therapy; POC = point-of-care device; PT = prothrombin time; VTE = venous thromboembolism; WHO = World Health Organization.

    INDEX TERMS
  • coagulation
  • ISI
  • OAT
  • © Copyright 2004 American Society for Clinical Laboratory Science Inc. All rights reserved.
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 17 (2)
American Society for Clinical Laboratory Science
Vol. 17, Issue 2
Spring 2004
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Oral Anticoagulants
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Oral Anticoagulants
David L McGlasson
American Society for Clinical Laboratory Science Apr 2004, 17 (2) 107-112; DOI: 10.29074/ascls.17.2.107

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Oral Anticoagulants
David L McGlasson
American Society for Clinical Laboratory Science Apr 2004, 17 (2) 107-112; DOI: 10.29074/ascls.17.2.107
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Unfractionated Heparin and Other Antithrombin Mediated Anticoagulants
  • Direct Thrombin Inhibitors
Show more Focus: Anticoagulation

Similar Articles

Keywords

  • coagulation
  • ISI
  • OAT

© 2025 The American Society for Clinical Laboratory Science

Powered by HighWire